Trial Profile
Phase 1B Trial of ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Advanced Pancreatic Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Oct 2020
Price :
$35
*
At a glance
- Drugs Pegargiminase (Primary) ; Gemcitabine; Paclitaxel
- Indications Pancreatic cancer
- Focus Adverse reactions
- Sponsors Polaris Pharmaceuticals
- 24 Sep 2020 Status changed from discontinued to completed.
- 03 Mar 2020 Status changed from active, no longer recruiting to discontinued.
- 18 Mar 2019 Planned End Date changed from 1 Sep 2018 to 1 May 2019.